Inclusion Criteria
o	No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear (within 7 days prior to treatment registration)
o	Platelet count >= 100 x 10^9/L (unless due to bone marrow infiltration by tumor, in which case platelet > 50,000/mm^3 is allowed) (within 7 days prior to treatment registration) 
o	Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except for patients with known Gilbert’s disease) (within 7 days prior to treatment registration) 
o	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (unless liver metastases are present in which case it must be =< 5 x ULN) (within 7 days prior to treatment registration)
o	Calculated creatinine clearance (Cockcroft-Gault equation) >= 30 mL/min (within 7 days prior to treatment registration) 
o	Able to swallow study drugs whole as a tablet/capsule
o	Patients who have partners of childbearing potential (e.g. female that has not been surgically sterilized or who are not amenorrheic for >= 12 months) must be willing to use a method of birth control in addition to adequate barrier protection as determined to be acceptable by the investigator during the study and for 3 months after last dose of niraparib administration and 5 months after the last dose of cetrelimab. In addition men should not donate sperm during this period. Please note that the efficacy of hormonal contraception may be decreased if administered with niraparib
o	Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria
•	Any chronic skin condition that does not require systemic therapy
•	Patients without active disease in the last 5 years may be included but only after consultation with the study physician
•	Patients with celiac disease controlled by diet alone
o	Receipt of live attenuated vaccination within 30 days of receiving cetrelimab (inclusion--- f) | 
o	Prisoners or subjects who are involuntarily incarcerated 
o	Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness
